

Prague 5-7 October 2017



UNDER THE AUSPICES OF











I am pleased to welcome you to the **4**th **International Symposium on Intra-Articular Treatment** in the beautiful city of Prague.

The ISIAT Symposium is held every two years, it moves across Europe and continuously gathers most relevant experts on different topics regarding Intra-Articular access, therapeutic targets, tools and future developments.

This edition features lectures and speeches by leading experts, in order to encourage discussions and stimulating interactions. Furthermore, it also hosts several practical courses of ultrasound-guided joint injections, applied to all kind of joints.

The ISIAT Symposium aims to give an outstanding opportunity to investigators and clinical practitioners to show their latest researches in selected oral presentations or posters and to create a unique, interdisciplinary and stimulating environment focused on developing a wide interchange and improvement of Intra-Articular management of joint diseases.

Prof. Alberto MiglioreCongress Chairman

Welcome and enjoy!

Congress Chairman

Alberto Migliore

Director of Unit of Rheumatology Ospedale San Pietro Fatebenefratelli Rome, Italy

President of National Foundation of ultrasound guided Hip-articular Therapy (ANTIAGE)

Scientific Secretariat

Giovanni Boni

Surgery of Sport Medicine Perugia, Italy

Local committee

Jitka Levorová

Department of Oral and Maxillofacial Surgery, Charles University and Faculty Hospital Prague, Czech Republic

Karel Pavelka

Department of Clinical and Experimental Rheumatology, Charles University and Faculty Hospital Prague, Czech Republic

Ladislav Šenolt

Department of Clinical and Experimental Rheumatology, Charles University and Faculty Hospital, Institute of Rheumatology


Prague, Czech Republic

Tomáš Trč

Department of Orthopaedic Surgery, Charles University and Motol University Hospital Prague, Czech Republic

Scientific Board

Raveendhara R. Bannuru, USA
Xavier Chevalier, France
Cosimo De Bari, UK
Demirhan Diracoglu, Turkey
Gabriel Herrero-Beaumont, Spain
Emmanuel Maheu, France
Raghu Raman, UK
Sandro Tormenta, Italy



Secretariat and registration desk

The on-site registration desks will open according to the schedule below:

- Thursday 5 October 2017 10.00-19.00
- Friday 6 October 2017 08.00-19.00
- Saturday 7 October 2017 08.00-17.00

Language

The official language is English

No simultaneous translation will be provided

Exhibition

An exhibition of pharmaceutical and technical products will take place in the Congress Venue throughout the Meeting.

Opening ceremony

The Opening Ceremony of the Congress takes place on **5 October at 16.00** in the **Congress Hall**

Mobile phone & photo

Participants are kindly requested to keep their mobile phones switched off in session halls and refrain from taking pictures during sessions.

Be connected



Wi-fi is available for Congress participants throughout the public areas of the venue. Each area of the hotel has its own net: Reception area: WiFi_Reception Congress area: CPPI-CPPII Lobby bar area: WiFi_LobbyBar Password is not necessary to connect to the Wi-fi. Should you need assistance, please ask

Non smoking policy

our hostesses at the Registration desk.



The ISIAT congress is a non-smoking event. Smoking in the Congress area is not allowed.

Liability and insurance

The Congress Secretariat and Organiser cannot accept liability for personal accidents or loss or damage to private property of participants, either during or as result of the Congress. Participants are advised to take out their own personal travel and health insurance for their trip.

Safety and security

Please do not leave bags or suitcase unattended at any time, whether inside or outside the session halls.

Privacy disclosure and publishing of images

Pursuant to article 13 of Legislative Decree no. 196/2003, the personal data of the participants, their videos and photos made during the event, will be used by AIM Italy s.r.l. for purposes related to the communication and the valorisation of the event. Such personal data will be communicated only to those people who are in charge of the activities necessary to the aforementioned purposes. Photos and videos will be also published on the website and social networks of AIM Group International (and on the website and social networks of the event, if any). The treatment will be carried out with appropriate tools ensuring security and confidentiality and may be also carried out by computerized tools that are able to memorize, manage and transmit the personal data. The data controller is AIM Italy s.r.l., with legal seat in Milan, Via Giuseppe Ripamonti 129. VAT no. 00943621003.

E-mail address info.aimcongress@aimgroup.eu. With regard to the personal data granted, included photos and videos, each participant can exercise the rights set forth in article 7 of Legislative Decree n. 196/2003 by contacting the data Controller.

Registration Fees

All fees are 21% Czech VAT included

ONSITE		THE DELEGATE FEE INCLUDES	
Delegate ANTIAGE & SIR member	€ 390,00	Admission to the scientific sessionsComplete meeting materials	
Delegate NON member	€ 520,00	✓ Attendance certificate	
Delegate from developing countries	€ 300,00	Access to the exhibition and poster areaCoffee breaks and box lunches	

For all Congress delegates and Faculty members, coffee breaks and box lunches will be served in the Exhibition area (2nd floor)

Practical Sessions Fees

Practical sessions are not included in the congress registration fee. To attend them please finalize the relevant registration.

I practical session	€ 100,00
2 practical sessions	€ 160,00
3 practical sessions	€ 200,00

The aim of the courses is to demonstrate the feasibility and the safety of ultrasound-guided intra-articular injections. The courses will have a theoretical-practical approach, with tutors, ultrasound machines and human models. This will provide all participants with a good knowledge both of ultrasound imaging of joint anatomy and of different techniques of ultrasound-guided injection of the joints.

Payment

- Credit Card: all major credit cards are accepted (American Express, Visa, Eurocard-Master Card)
- Cash: payments will be accepted in Euro only

Congress name badge

Participants are kindly requested to wear their badge during all sessions. Congress badges are personalized with the following colors:

DELEGATES	WHITE
FACULTY	RED
EXHIBITORS	GREEN
PRESS	YELLOW

To receive your certificate

The certificate of attendance will be available after completing the online evaluation form. The process will take no more than 5 minutes. We thank you for your feedback as it is important to us and helps improve future activities. Please check we have your correct email address at the Registration desk.

Hotel International Prague

Koulova, 15 - 160 00 Prague 6 - Czech Republic

How to reach the venue

The nearest underground stop is **Dejvicka** (green line A). From this stop, the hotel is easily reachable by bus (only one stop by bus nr. 107, 116, 160 or 147 - **Čínská** stop)

From the Airport

Bus 119 from the Airport to *Nádraží Veleslavín* stop. Change to underground A (green line) - direction *Depo Hostivař* - until *Dejvicka* stop.

Taxi

20 minute taxi ride, estimated fare: € 25,00

From Prague Main Railway Station (Hlavní Nádraží)

Underground C (red line) - direction Háje - one stop from Hlavní Nádraží to Muzeum stop. Change to underground A (green line) - direction Depo Hostivař - until Dejvicka stop

From Holešovice Railway Station

Underground C (red line) - direction Háje - 3 stops from Nádraží Holešovice to Muzeum stop. Change to underground A (green line) - direction Depo Hostiva - until Dejvicka stop



Abstract submission

For each accepted abstract, an author is expected to attend the congress and make the poster or oral presentation.

Young Italian Researchers (under 40)

All presenting authors of accepted oral communications or posters, aged 40 or under, who are currently Residents in Italian Medical Schools, in Rheumatology, Physical Medicine and Rehabilitation, Orthopaedics or Sports Medicine are entitled to complimentary registration.

Young researchers MUST be 40 or under on October 5, 2017.

Information for Presenters

Slide Centre

A slide centre will be available throughout the entire Congress for Speakers and Authors of oral communications. The room is located at the ground floor of the hotel, close to the main Session Hall.

All Speakers/Authors are expected to produce a PowerPoint presentation.

Presentations should be saved on a USB memory stick and delivered to the slide centre either the day before the session or at least two hours before the beginning of the session. PCs at the slide centre will be available to make changes to the presentation. The use of the Speakers' own laptop for presentation is not allowed.

Oral Presentations (for Speakers and Authors)

These few instructions are provided to let Speakers and Authors prepare a presentation that will allow the audience to get the maximum benefit from their speech, and will enable the Organisers to ensure that the sessions will be conducted smoothly.

Presentations have to be prepared in Microsoft PowerPoint format with Windows 7 (or higher) and PowerPoint 2010 (or higher) and should be PC formatted (not Mac formatted).

The recommended format for PowerPoint presentations is 16:9.

We recommend that Speakers and Authors

are allowed to use the photos contained in their presentations and disclose the source. Please bring a backup copy of your presentation with you. You should copy your PowerPoint and all movies to a folder on a USB thumb drive. PowerPoint does NOT embed movies. They must be placed in the same folder as your PowerPoint.

Use high-contrast lettering and readable standard font (minimum font size 24); use high-contrast colors: light text on dark background or vice versa.

If Speakers and Authors create their presentations using a different system from MS Windows (such as Mac or Linux), they are kindly requested to provide presentations in a Windows compatible format and to go to the slide centre to fix possible compatibility issues with technicians.

Time keeping is crucial: practice your presentation in advance and ensure that you stay in time:

- the presentation should be kept strictly within the timeframe given to you;
- the Moderators will keep strict time control during the presentations;
- a countdown clock will be provided, keep an eye on it.

Posters

All posters will be on display for the duration of the Congress from 5 to 7 October.

Each poster has been given a number and should be fixed to the board marked with the same number.

Set up time: 5 October from hrs 12.00 Dismantle time: 7 October from hrs 15.30 Each Author is asked to stand by their poster during lunch time on 6 and 7 October to reply to possible questions from participants. We suggest you bring some business card with you to be left close to your board in case you cannot guarantee your presence during lunch time.

The Organiser are not responsible for loss of any posters that have not been removed by the end of the sessions.

Grants



The Italian Society of Rheumatology (SIR) has provided 8 grants to participants selected for oral or poster presentations which have reached a

high score and found to be particularly meritorious by the Referees. The grant of \in 1000,00 gross will be recognized directly by SIR to the authors of selected abstracts.

CME Provider

AIM Education - Provider n. 93 | Via G. Ripamonti, 129 - 20141 Milan, Italy Tel. +39 02 56601.1 - Fax +39 02 70048585 | cme@aimgroup.eu - www.aimeducation.it

ECM - Educazione Continua in Medicina

L'evento è inserito nel Piano Formativo anno 2017 AIM Education - Provider nr. 93. È stata inviata una richiesta di accreditamento alla Commissione Nazionale per la Formazione Continua con Obiettivo Formativo tecnico-professionale: contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, malattie rare (18) per le seguenti Figure Professionali con specializzazione nelle seguenti discipline per un numero massimo di 210 partecipanti.

Professione: MEDICO CHIRURGO

Disciplina: Allergologia ed immunologia clinica, Anatomia patologica, Anestesia e rianimazione, Biochimica clinica, Cardiologia, Dermatologia e venereologia, Farmacologia e tossicologia clinica, Genetica medica, Geriatria, Malattie dell'apparato respiratorio, Malattie infettive, Malattie metaboliche e diabetologia, Medicina fisica e riabilitazione, Medicina generale (medici di famiglia), Medicina interna, Medicina legale, Medicina termale, Nefrologia, Ortopedia e traumatologia, Patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia), Pediatria, Pediatria (pediatri di libera scelta), Reumatologia, Radiologia diagnostica.

Professione: INFERMIERE

Disciplina: Infermiere, Infermiere pediatrico

Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una presenza documentata ad almeno il 90% della durata. ID ECM: 93-201243 - ECM in fase di valutazione.

hrs	CONGRESS HALL	NEKLAN HALL	VLASTA HALL	POSTER AREA
10.00	Opening Registrations and Exhibition			
11.30-13.00		Practical Course: Ankle	Practical Course: Knee	
13.00-14.30		Practical Course: Shoulder	Practical Course: Hip	
14.30-16.00		Practical Course: Hand and Wrist	Practical Course: Sacroiliac Joint	
16.00-16.30	OPENING CEREMONY			
16.30-17.00	MAIN LECTURE			POSTERS
17.00-18.00	FIRST SESSION			

Programme at a Glance Friday 6 October

NEKLAN HALL VLASTA HALL hrs **CONGRESS HALL** POSTER AREA 08.30-09.45 SECOND SESSION 09.45-10.15 **LECTURE** 10.15-10.45 THIRD SESSION 10.45-11.15 Coffee break in the exhibition area INDUSTRY-SPONSORED 11.15-11.55 SATELLITE SESSION 11.55-12.40 **FOURTH SESSION** INDUSTRY-SPONSORED 12.40-13.00 SATELLITE SESSION 13.00-14.00 Box lunch in the exhibition area **POSTERS INDUSTRY-SPONSORED** 14.00-14.20 SATELLITE SESSION 14.20-15.00 ORAL COMMUNICATIONS 15.00-16.15 DEBATE 16.15-16.45 Coffee break in the exhibition area **INDUSTRY-SPONSORED** 16.45-17.25 **SATELLITE SESSION** 17.25-18.40 FIFTH SESSION 18.40-19.00 **LECTURE**

hrs	CONGRESS HALL	NEKLAN HALL	VLASTA HALL	POSTER A
08.30-09.15	SIXTH SESSION			
09.15-10.15	SEVENTH SESSION			
10.15-10.35	INDUSTRY-SPONSORED SATELLITE SESSION			
10.35-11.05	Coffee break in the exhibition area			
11.05-12.05	EIGHTH SESSION			2007
12.05-12.25	INDUSTRY-SPONSORED SATELLITE SESSION			POSTI
12.25-13.10	ROUND TABLE			
13.10-14.10	Box lunch in the exhibition area			
14.10-15.40	ORAL COMMUNICATIONS			
15.40-16.40	Practical Course: Elbow	Practical Course: Facet Joints	Practical Course: Temporomandibular Joint	

Thursday 5 October

11.30-13.00 Practical Course: Ankle
B. Goncalves (Coimbra, PRT)

13.00-14.30 **Practical Course: Shoulder** *B. Goncalves (Coimbra, PRT)*

14.30-16.00 Practical Course: Hand and Wrist A. De Marchi (Turin, ITA)

VLASTA HALL

NEKLAN HALL

11.30-13.00 Practical Course: Knee O. De Lucia (Milan, ITA)

13.00-14.30 **Practical Course: Hip** *S. Tormenta (Rome, ITA)*

14.30-16.00 Practical Course: Sacroiliac Joint S. Tormenta (Rome, ITA)

CONGRESS HALL

16.00-16.30 OPENING CEREMONY Welcome greetings





Thursday 5 October

16.30-17.00 MAIN LECTURE

Chairman: R. Raman (Cottingham, GBR)

Are all placebos created equal?

R.R. Bannuru (Boston, USA)

17.00-18.00 FIRST SESSION

Chairman: C. De Bari (Aberdeen, GBR)

Update on tribosupplementation

G. Jay (Providence, USA)

Safety of 2-carba cyclic phosphatidic acid (2ccPA) for intraarticular administration

I. Masuda (Tokyo, JPN)

Fasitibant in patients with symptomatic osteoarthritis of the knee

K. Pavelka (Prague, CZE)

Ultrasound as a guidance for intra-articular therapy: no alternative is possible

L. Sconfienza (Milan, ITA)

Thursday 5 October

Friday 6 October

CONGRESS HALL

08.30-09.45 **SECOND SESSION**

Chairmen: X. Chevalier (Créteil, FRA), T. Trč (Prague, CZE)

The challenge of treating niched cells into the joint

C. De Bari (Aberdeen, GBR)

Autologous fat tissue extract for intra-articular use: differences in preparation and clinical evidence

G. Spinetti (Milan, ITA)

Clinical experiences with fat tissue extracts in joint disorders F. Adriani (Rome, ITA)

Efficacy of intra-articular bone marrow concentrate injection in osteoarthritis

H. Vincent (Los Angeles, USA)

Preliminary data from ADIPOA consortium

C. Jorgensen (Montpellier, FRA)

09.45-10.15 **LECTURE**

Chairman: K. Pavelka (Prague, CZE)

The challenge in the world for intra-articular treatment - an overview

A. Migliore (Rome, ITA)

Friday 6 October

10.15-10.45 THIRD SESSION Chairman: L. Šenolt (Prague, CZE) Have different PRP formulations the same properties? I. Andia (Barakaldo, ESP) Overview on the use of PRP in tendons J.H.C. Wang (Pittsburgh, USA) 10.45-11.15 Coffee break in the exhibition area – 2nd floor NO CME 11.15-11.55 INDUSTRY SPONSORED SATELLITE SESSION 11 55-12 40 **FOURTH SESSION** Chairmen: B. Frediani (Siena, ITA), G. Herrero-Beaumont (Madrid, ESP) Intra-articular treatment of rheumatoid arthritis in the era of treat-to-target strategy L. Šenolt (Prague, CZE) Intra-articular therapy in inflammatory rheumatic diseases K. Pavelka (Prague, CZE) The challenge of hand osteoarthritis: may be a role for intra-articular injections of small joints? R.N.V. Furtado (São Paulo, BRA) NO CME 12.40-13.00 INDUSTRY SPONSORED SATELLITE SESSION 13.00-14.00 Box lunch in the exhibition area – 2nd floor

13.00-14.00 **POSTER TOUR - 2nd floor**

Friday 6 October

NO CME



14.20-15.00 ORAL COMMUNICATIONS
Chairman: O. De Lucia (Milan, ITA)

14.20-14.30 Comparison of efficiency between intra-articular concentrate growth factor and conventional physical treatment in patients with knee osteoarthritis H. $\ddot{\text{O}}\text{zkan}^{\text{1}}$ [$^{\text{1}}\text{Bolu}$, TUR]

NO CME

14.30-14.40 Treatment option in moderate hip osteoarthritis by needle lavage, triamcinolone and hylan G-F20

M. Rezende¹, H. Gurgel¹, G. Campos², M. Hissadomi¹, R. Frucchi¹, T. Pasqualin¹, A. Pailo¹

[¹São Paulo, BRA; ²Campinas, BRA]

14.40-14.50 Ultrasonograhpic evaluation of hyaluronic acid effectiveness in the treatment of knee osteoarthritis with synovial involvment S. Parisi¹, M. Scarati¹, M. Priora¹, R. Borrelli¹, A. Laganà¹, C.L. Peroni¹, M.C. Ditto¹, E. Fusaro¹

14.50-15.00 The response rate to viscosupplementation is depending on the choice of the patient reported outcomes (pros) in patients with knee osteoarthritis

T. Conrozier¹, R. Raman² [¹Belfort, FRA; ²Cottingham, GBR]

Friday 6 October

15.00-16.15 DEBATE: VS AND INTRA-ARTICULAR PRP IN COMPARISON Chairmen: X. Chevalier (Créteil, FRA), J.J. Scali (Buenos Aires, ARG)

PRP is better than VS

H.R. Dehghan (Yazd, IRN)

VS is better than PRP

G. Filardo (Bologna, ITA)

Is the association a good chance?

R. Papalia, (Rome, ITA)

Discussion

16.15-16.45 Coffee break in the exhibition area - 2nd floor

16.45-17.25 INDUSTRY SPONSORED SATELLITE SESSION



Friday 6 October

17.25-18.40 **FIFTH SESSION**

Chairmen: R. Raman (Cottingham, GBR), J.J. Scali (Buenos Aires, ARG)

Decision algorithms for VS re-treatment from the EUROpean VIScosupplementation Consensus group (EUROVISCO) *T. Conrozier (Trévenans, FRA)*

VS in the management of osteoarthritis: the ESCEO perspective *G. Herrero-Beaumont (Madrid, ESP)*

Why international recommendations for knee OA management should consider HA intra-articular injections as a treatment option *E. Maheu (Paris. FRA)*

The scientific statement of American Medical Society for Sport Medicine (AMSSM) concerning viscosupplementation of knee osteoarthritis

T. Trojian (Philadelphia, USA)

I.S.Mu.L.T. recommendations on VS

C. Foti (Rome, ITA)

18.40-19.00 **LECTURE**

Chairman: E. Maheu (Paris, FRA)

The cost-effectiveness of VS and the challenge for reimbursement in Europe for ostearthritis patients

D. Integlia (Rome, ITA)

Friday 6 October

Saturday 7 October

CONGRESS HALL

08.30-09.15 SIXTH SESSION - THE CHALLENGE OF MULTIPLE OSTEOARTHRITIS

PHENOTYPE: THE SUBCHONDRAL BONE INVOLVEMENT Chairmen: B. Frediani (Siena - ITA), L. Šenolt (Prague, CZE)

How to differentiate the osteoarthritis fenoptype with subchondral bone involvement

G. Herrero-Beaumont (Madrid, ESP)

The EBM of IA bisphosphonates

L. Idolazzi (Verona, ITA)

There is a rationale for the association of systemic bisphosphonate with VS?

U. Massafra (Rome, ITA)

Saturday 7 October

09.15-10.15 **SEVENTH SESSION**

Chairmen: C. Foti (Rome, ITA), T. Trč (Prague, CZE)

Locomotor pattern of muscle activity after VS

A.C.W. Tang (Linkou, TWN)

Effect of viscosupplementation on quality of life and functional capacity in knee osteoarthritis

P. Hamdan (Rio de Janeiro, BRA)

Single versus multiple dose hyaluronic acid: pro and cons D. Diracoglu (Instanbul, TUR)

Viscosupplementation in the osteoarthritis of the ankle

A. Witteveen (Nijmegen, NLD)

10.15-10.35 INDUSTRY SPONSORED SATELLITE SESSION



10.35-11.05 Coffee break in the exhibition area - 2nd floor

11.05-12.05 FIGHTH SESSION - FROM FIELD TO THE FIELD

Chairmen: P. Hamdan (Rio de Janeiro, BRA), T. Trojian (Philadelphia, USA)

Management of the high level competitive athlete after musculoskeletal trauma: is intra-articular injection useful for a quick recovery?

V. Ieracitano (Genoa, ITA)

Imaging: timing and suggestions for the IA management of athletes S. Giannini (Rome, ITA)

Coming back to competition; the right timing of IA administration in high level athletes *G. Boni (Perugia, ITA)*

12.05-12.25 INDUSTRY SPONSORED SATELLITE SESSION



12.25-13.10 ROUND TABLE - ORAL NSAIDS IN COMPARISON OR IN COMBINATION WITH INTRA-ARTICULAR TREATMENTS (HA AND CS) IN THE MANAGEMENT OF OSTEOARTHRITIS

Chairmen: J. Monfort (Barcelona, ESP), R. Raman (Cottingham, GBR)
Panelists: R.R. Bannuru (Boston, USA), G. Gigliucci (Rome, ITA),
J. Jerosch (Neuss, DEU)

13.10-14.10 Box lunch in the exhibition area - 2nd floor

13.10-14.10 **POSTER TOUR - 2**nd **floor**



14.10-15.40	ORAL COMMUNICATIONS Chairman: J. Jerosch (Neuss, DEU)
14.10-14.20	Recombinant human proteoglycan-4 (rhPRG4) inhibits monosodium urate (MSU) crystal phagocytosis by human macrophages and resultant inflammatory response G. Jay¹, M. Qadri², T.A. Schmidt³, K.A. Elsaid⁴, W. Wong¹ [¹Providence, USA; ²Boston, USA; ³Calgary, CAN; ⁴Irvine, USA]
14.20-14.30	Multicenter open-label trial assessing safety and efficacy of a single injection of mannitol-modified crosslinked hyaluronic acid in trapezometacarpial osteoarthritis T. Conrozier¹, H. Lellouche², J. Porterie³, S. Mellac-Ducamp⁴, C. Rizzo⁵, B. Maillet⁶ [¹Belfort, FRA; ²Paris, FRA; ³Auch, FRA; ⁴Nevers, FRA; ⁵Lyon, FRA; ⁶Moulins, FRA]
14.30-14.40	Haematopoietic fresh stem cells CD34 positive and the ankle joint cartilage treatment <i>M. Krochmalski</i> ¹ [¹Lodz, POL]
14.40-14.50	Hyaluronic acid (MW 1,500–2,000 kDa) in symptomatic hip OA - 8 years follow up U. Massafra ¹ , G. Gigliucci ¹ , S. Tormenta ¹ , A. Migliore ¹ [¹Rome, TA]
14.50-15.00	Surgical management of TMJ involvement in patients with rheumatoid diseases J. Levorová¹, V. Machon¹, R. Foltan¹ [¹Prague, CZE]

15:00-15:10 Yttrium-90 radiosynovectomy in camptodactyly-arthropathy-coxa vara-pericarditis syndrome S. Al-Mayouf¹, N. AlMutairi¹, K. Alismail¹ [1Riyadh, SAU] 15:10-15:20 Joint pain therapy: an algorithm of use A. Piccinato¹, R. Fava¹ [¹Latina, ITA] 15:20-15:30 Injection of stem cell, hyaluronic acid and prolotherapy in dog and bovine joints. Experience of a veterinary clinic P. Boni¹ [1Cannara (PG), ITA] 15:30-15:40 Hyaluronic acid/sorbitol complex is able to preserve cellular metabolism of chondrocytes in human OA O. Shi¹, H. Benabdoun¹, H. Fahmi¹, J.C. Fernandes¹, M. Benderdour¹ [1Montréal, CAN] **CONGRESS CLOSING** NO CME NFKI AN HALL 15.40-16.40 Practical Course: Facet Joints L. Di Sante (Rome, ITA) NO CME **VLASTA HALL** 15.40-16.40 Practical Course: Temporomandibular Joint J. Levorová (Prague, CZE) NO CME **CONGRESS HALL** 15.40-16.40 Practical Course: Elbow

S. Giannini (Rome, ITA)



POSTER AREA

POO1 EFFECTS OF A PERSONALIZED TREATMENT WITH HYALURONIC ACID IN SPORTS PEOPLE WITH HIP OSTFOARTHRITIS. PREI IMINARY MNR OBSERVATIONS

G. Rando¹, R. Pastorino², F. Chiacchio², F. Franzé¹

[1Alba (CN), ITA; 2Novi Ligure (AL), ITA]

PO02 THE COMPARISION OF THE EFFECT ONLY SUBACROMIAL CORTICOSTEROID INJECTION AND THE

COMBINATION OF SUBACROMIAL CORTICOSTEROID INJECTION AND SUPRASCAPULAR NERVE

BLOCK (SSNB) WITH SHOULDER IMPINGEMENT SYNDROME (SIS)

E. Yilmaz¹ [¹Kocaeli, TUR]

PO03 IMPORTANCE OF ILIOLUMBAR LIGAMENT (ILL) IN OSTEOARTHRITIS OF THE HIP

L. Wolenski¹ [¹Cesena, ITA]

PO04 INTRA-ARTICULAR ANTI TNF ALPHA THERAPY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

M. Vidovic¹, L. Lamot¹, M. Lamot¹, M. Harjacek¹

[¹Zagreb, HRV]

PO05 IT'S POSSIBLE TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH KNEE OSTEOARTHRITIS BY

APPLYING PLATELET-RICH PLASMA? WHICH PROTOCOL IS BETTER? V. Vaquerizo¹, V. Moreno¹, E. Montes¹, M. Ruiz de Castañeda¹, M. García-Lopez¹

[¹Alcalá de Henares, ESP]

PO06 THE EFFECT OF ULTRASONOGRAPHIC ASPIRATION IN THE TREATMENT OF BAKER'S CYST

N. Tas¹, H. Uzkeser¹, A. Erdal¹

[¹Erzurum, TUR]

PO07 TREATMENT EFFECT OF SONO-GUIDED SUPRAPATELLAR BURSA EFFUSION ASPIRATION ON KNEE

OSTEOARTHRITIS

F. Tang¹, T. Chen², C. Tang¹ [¹Taoyuan, TWN; ²Taipei, TWN]

PO08 PROSPECTIVE. MONOCENTRIC. POST-CE MARK STUDY TO ASSESS EFFICACY AND SAFETY OF HYADD 4 INTRA-ARTICULAR INJECTION IN ACTIVE PATIENTS AFFECTED BY KNEE OVERUSE SYNDROME PRELIMINARY RESULTS V. Santilli¹. A. Bernetti¹ [1Rome, ITA] PO09 OSTEO-SYNTHESIS OF INTRA-ARTICULAR FRACTURES OF DISTAL END RADIUS USING LOCKING COMPRESSION PLATES M. Khanna¹, S. Arora¹, S. Chandraker¹ [¹Rohtak, IND] PO10 COMPARISON OF THREE TREATMENT PROTOCOLS WITH INTRA-ARTICULAR LOW OR INTERMEDIATE MOI FCUI AR WEIGHT HYAI URONIC ACID IN FARLY SYMPTOMATIC KNEF OSTFOARTHRITIS F. Galluccio¹, M. Capassoni¹, M. Matucci Cerinic¹ [1Florence, ITA] PO11 TWO YEAR EFFICACY OF QUARTERLY INTRA-ARTICULAR HYALURONIC ACID (HA) FOR KNEE OSTEOARTHRITIS F. Galluccio¹, E. Bellucci¹, M. Matucci Cerinic¹ [¹Florence, ITA] PO12 AN EXPERIENCE OF APPLICATION OF SOME VARIETIES OF CELLULAR THERAPY FOR DEGENERATIVE LEISON OF JOINTS S. Chornobav¹, S. Martsiniak¹, G. Bondariev¹ [¹Kviv. UKR] PO13 COMPARING STEROID AND HYALURONIC ACID ON TREATING KNEE OSTFOARTHRITIS WITH ISOKINETIC MUSCLE STRENGTH ON FIRST WEEK AND FIRST MONTH T. Chen¹, F. Tang², C. Tang² [¹Taipei, TWN: ²Tao-Yuang, TWN] BIOCHEMICAL PARAMETERS IN GONARTHROSIS ASSESSMENT FOLLOWING INTRA-ARTICULAR PO14 TREATMENT OF HYALURONIC ACID I. Capparucci¹, P. Sestili¹, E. Barbieri¹ [1San Benedetto Del Tronto (AP), ITA]

PO15	OUR EXPERIENCE OF APPLYING CYTOKINE THERAPY AT TREATING CHRONIC KNEE SYNOVITIS CAUSED BY A CONSTANT STRESS G. Bondariev ¹ , I. Roy ¹ , S. Martsynyak ¹ , S. Chornobay ¹ [¹Kyiv, UKR]
PO16	EVALUATION OF ASSOCIATED MENISCAL AND CHONDRAL INJURIES AND THEIR MANAGEMENT IN PATIENTS UNDERGOING ARTHROSCOPIC ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION R. Arya ¹ , P. Gupta ¹ [¹New Delhi, IND]
PO17	PORCINE COLLAGENE FOR INTRA-ARTICULAR TREATMENT OF KNEE CHONDROCALCINOSIS G. Gigliucci ¹ , F. Giovannangeli ¹ , U. Massafra ¹ , A. Migliore ¹ [¹Rome, ITA]
PO18	CASE SERIES OF HYADD 4 IN HIP OA F. Giovannangeli¹, G. Gigliucci¹, U. Massafra¹, S. Tormenta¹, A. Migliore¹ [¹Rome, ITA]
PO19	USE OF STEROID INJECTIONS FOR THE TREATMENT OF DACTYLITIS IN PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW G. Tramontano ¹ , M. Gilio ¹ , S. D'Angelo ¹ , G. Abignano ¹ , I. Olivieri ¹ [¹Potenza, ITA]
PO20	REAL LIFE DATA ABOUT EFFICACY AND SAFETY OF INTRA-ARTICULAR VISCOSUPPLEMENTATION WITH MEDIUM-CHAIN HYALURONIC ACID: A MULTICENTRIC RETROSPECTIVE OBSERVATIONAL STUDY S. Gentileschi ¹ , M. Bardelli ¹ , E. Garcia-Gonzalez ¹ , G.M. Guidelli ² , M. Galeazzi ¹ [¹Siena, ITA; ²Rozzano (MI), ITA]
PO21	EFFICACY OF ULTRASOUND-GUIDED INTRA-ARTICULAR HYALURONAN FOR HIP OSTEOARTHRITIS G.M. Guidelli ¹ , E. Generali ¹ , A. Ceribelli ¹ , M. De Santis ¹ , C. Selmi ¹ [¹ Rozzano (MI), ITA]
PO22	HYALURONIC ACID/SORBITOL COMPLEX IMPROVES CARTILAGE MATERIAL PROPERTIES C. Lavet ¹ , A. Adamczewski ¹ , I. Badoud ¹ , P. Ammann ¹ [¹Geneva, CHE]

Industry Sponsored Satellite Sessions



Friday 6 October

CONGRESS HALL

11.15-11.55 IBSA SATELLITE SESSION

HYBRID COOPERATIVE COMPLEXES OF HYALURONIC ACID (NAHYCO® TECHNOLOGY):
INNOVATION IN VISCOSUPPI EMENTATION

Chairman: L. Šenolt (Prague, CZE)

Welcome and introduction

L. Šenolt (Prague, CZE)

The "hybrid cooperative complexes" of high and low MW hyaluronic acid (NAHYCO® technology): what's behind in practice M. Abate (Chieti, ITA)

Clinical experience with Sinovial® HL, the new product based on NAHYCO® technology

M. Varga (Košice, SVK)

Discussion and conclusion

L. Šenolt (Prague, CZE)

12.40-13.00 FIDIA SATELLITE LECTURE

Chairman: G. Boni (Rome, ITA)

Developing expertise in OA management with IAHA treatment *K. Pavelka (Prague, CZE)*

Friday 6 October

14 00-14 20 APTISSEN SATELLITE LECTURE

How to explain the long term efficacy of intra-articular injection of hyaluronic acid based product?

P. Ammann (Geneva, CHE)

16.45-17.25 ABIOGEN SATELLITE SESSION

MANAGING INTRA-ARTICULAR INFLAMMATION IN OA

The management of inflammation in OA

S. Crimaldi (Lucca, ITA)

Cross linked HA plus ancillar steroid combination: a new option for OA

A. Migliore (Rome, ITA)

Saturday 7 October

10.15-10.35 GUNA SATELLITE LECTURE

Chairman: D. Diracoglu (Instanbul, TUR)

Evidences and new therapeutic opportunities of Collagene Medical Devices. The JOINT study

A. Migliore (Rome, ITA)

12.05-12.25 FIDIA ITALY SATELLITE LECTURE

Prospective, monocentric, post-CE mark study to assess efficacy and safety of Hymovis® ONE (32 mg/4 ml) intra-articular injection in active patients affected by knee overuse syndrome A. Bernetti (Rome, ITA), V. Santilli (Rome, ITA)

Friday 6 October

Μ.	A	b	at	e,	Ital
_	_				

E. Adriani, Italy

P. Ammann, Switzerland

I. Andia, Spain

R.R. Bannuru, USA

A. Bernetti, Italy

G. Boni, *Italy*

X. Chevalier, France

T. Conrozier, France

S. Crimaldi, Italy

C. De Bari, UK

O. De Lucia, Italy

A. De Marchi, Italy

H.R. Dehghan, Iran

L. Di Sante, Italy

D. Diracoglu, Turkey

G. Filardo, *Italy*

C. Foti, Italy

B. Frediani, Italy

R.N.V. Furtado, Brazil

S. Giannini, Italy

G. Gigliucci, *Italy*

B. Gonçalves, Portugal

P. Hamdan, Brazil

G. Herrero-Beaumont, Spain

L. Idolazzi, Italy

V. leracitano, Italy

D. Integlia, *Italy*

G. Jay, USA

J. Jerosch, Germany

C. Jorgensen, France

J. Levorová, Czech Republic

E. Maheu, France

N. Martusevich, Belarus

U. Massafra, Italy

I. Masuda, Japan

A. Migliore, Italy

J. Monfort, Spain

R. Papalia, Italy

K. Pavelka, Czech Republic

R. Raman, UK

V. Santilli, Italy

J.J. Scali, Argentina

L.M. Sconfienza, Italy

L. Šenolt, Czech Republic

G. Spinetti, Italy

A.C.W. Tang, Taiwan

S. Tormenta, Italy

T. Trč, Czech Republic


T. Trojian, USA

M. Varga, Slovak Republic

H. Vincent, USA

J. H.-C. Wang, USA

A. Witteveen, The Netherlands



EXHIBITOR	воотн
APTISSEN	ı
T-LAB	2
VSY BIOTECHNOLOGY	4
TOSHIBA	5
YURIA PHARM	6
REGENYAL LABORATORIES	8
GUNA	9
FIDIA PHARMA GROUP	10
HTA MEDICA	Ш
IBSA	12-13

Organizing Secretariat

AIM Group International GROUP Milan Office

Via G. Ripamonti, 129 - 20141 Milan, Italy Ph. +39 02 566011 - Fax +39 02 70048578 isiat2017@aimgroup.eu

ABIOGEN PHARMA SPA

Abiogen Pharma is a family business reality that has been growing, in the Italian pharmaceutical landscape, for more than four generations. The wealth of scientific and technological knowledge is the strong feature of this company that aims to combine the Italian model of medium-size company with that of a modern, flexible and innovative enterprise.

The main therapeutic areas of Abiogen Pharma are: Bone Metabolism, Pain, Viscosupplementation, Respiratory, Diabetes, Dermatology.

APTISSEN SA

Aptissen SA is a company specialized in the research & development, manufacturing and commercialization of biopolymer-based medical devices. Aptissen SA stands for Advanced Polymer for TISSue ENgineering, which clearly gives a hint about the company's skills. Aptissen is an innovative company focusing on the development of next generation products with the goal to become a market-leader in injectable biopolymers-derived devices in Healthcare. Already being a major player in the use of Hyaluronic Acid our mission is to develop and make available worldwide the best quality injectable products to meet patients' expectations

FIDIA PHARMA GROUP

Fidia Pharma Group is a privately held, fully integrated Italian healthcare company, with R&D, manufacturing, marketing and sales capabilities. The Company was founded in 1946 and is headquartered in Abano Terme (Italy).

The company's overall objective is establishing its leadership, through developing and marketing innovative pharmaceutical products, medical devices and healthcare 'lifestyle' products, primarily based on hyaluronic acid (HA) and its derivatives, thereby providing patients and healthcare professionals with a variety of treatment options, in strategic areas, such as Bone and Joint Care, Wound Healing, Mucosal Care, Neuroscience, Ophthalmology, and Aesthetic Medicine.

Over 50 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of molecular weight. Manufacturing operations are FDA-approved, and comply with the strictest international regulations and safety standards.

Fidia extends its global reach through local partners in 100 countries worldwide, and wholly-owned subsidiaries in USA, Kazakhstan, Germany, Spain, Russia, Middle East, Czech and Slovak Republics.

GUNA - a fully Italian company

Founded in 1983, GUNA S.p.a. has rapidly become the leading Italian Company in the production and distribution of complementary medicine and health products of natural origin.

Today, GUNA has an extraordinary staff of over 250 employees. Its manufacturing facility, located in Milan, is among the most advanced of the industry.

The Company's wide product range includes low-dose medicinal products, medical devices, cosmetics, Bach flowers, a cutting-edge line of unique and innovative Nutraceuticals, and a range of complementary feed for cats and dogs.

The medical devices line, based on swine-derived collagen and ancillary substances of natural origin, offers a refined and innovative approach to the treatment of painful disease affecting the musculoskeletal system. GUNA products are exported to over 30 Countries in the world, including a subsidiary in the USA.

Every year, considerable resources are invested for research and development.

GUNA supports several medical and professional associations that provide intensive educational and training programmes to medical doctors, pharmacists and healthcare practitioners.

HTA MEDICA - TISS'YOU

Tiss'You was born with the goal of becoming the first true "European Biological Company" able to develop, produce and certify medical devices and biomaterials for regenerative medicine.

Within the new research and production facility it will be a real "Tiss'You Lab" medical centre, where ambulatory and surgical activities will be carried out with the specific target of regenerative and mini-invasive medicine.

IBSA INSTITUT BIOCHIMQUE SA

IBSA Institut Biochimque SA is a pharmaceutical company headquartered in Lugano, Switzerland. The company has developed a series of proprietary technologies allowing a qualitative upgrading of already available and widely-used molecules and therapeutic solutions. For OA and musculoskeletal disorders, IBSA's portfolio includes a wide range of pharmaceutical options such as a highly purified intra-articular hyaluronic acid of biofermentative origin (Sinovial®, Yaral®, Intragel®, Gelsyn-3™), pharmaceutical- grade chondroitin sulphate for oral intake (Condrosulf®, Chondrosulf®), topical and oral forms of diclofenac epolamine (Flector®) and an innovative low-dosage subcutaneous injection of diclofenac (Akis®, Dicloin®)

REGENYAL LABORATORIES

Scientific research and manufacture of products for Aesthetic Medicine and Orthopaedics, as well as dentistry and dermato-aesthetics. A combination that represents the essence of the activities of Regenyal Laboratories – a leading company in the production of a wide range of Hyaluronic acid-based injectable devices.

The distinctive trait of our products is the absolute safety of the substances. All products are rigorously Made in Italy and respect the "green injections" standard.

It is thanks to the high degree on scientificity and laboratory trials that Regenyal Laboratories created the Biorivolumetria: a highly innovative concept. The purpose of Biorivolumetria is to prevent and reduce skin ageing with the person's health in mind. The Biorivolumetria products represent a true revolution in the anti-aging field and make it possible to restore a natural and harmonious appearance to the skin.

The products that fall into the Biorivolumetria category and are currently available on the market are: Regenyal Idea Bio-Expander, Regenyal Idea Lips, Regenyal Idea, Regenyal Super Idea, Regenflex Bio-Plus. Each of these products is obtained by means of an innovative certified and patented manufacturing system.

T-LAB

T-Biotechnology was established as T-Biotechnology Laboratory Aesthetics and Co in 2012. T-LAB's main activity is regenerative medicine. T-LAB's personnel is qualified and experienced in the sector for many years also working as partners with the quality companies such as manufacturers and suppliers, experienced luminary doctors, dealers in the sector. T-LAB's first experience is acquired by manufacturing the PRP Kit according to all related standards. T-LAB has come from small office to its own manufacturing factory in Turkey with high quality standards.

TOSHIBA MEDICAL SYSTEMS

Toshiba Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Toshiba Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Toshiba Medical we work hand in hand with our partners – our medical, academic and research

community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.

VSY BIOTECHNOLOGY

VSY Biotechnology is a progressive and innovative company that focuses on consumer satisfaction by creating superior state-of-the-art intraocular lenses, viscoelastics for ophthalmology and viscosupplements for orthopedics designed and manufactured to greatly enhance and improve the life quality of patients around the globe.

Starting from foundation to today, quality and safety standards are the source of our success.

With our know-how in biotechnology, we will continue to enlighten the world by combining these disciplines for the patients.

YURIA-PHARM

Founded in 1998, YURiA-PHARM focused its efforts on production of infusions and as of today is a leading infusion manufacturer not only in Ukraine, but also in CIS, representing in Europe, Asia, Middle East, Africa. We supply medical facilities with more than 100

different solutions for infusions, medical devices etc. Our product line sums up to more than 40 infusions, completely covering the needs of medical facilities in infusion therapy; unique products used in gynecology, urology, orthopedics etc.



Lisboa 3-5 October 2019

Platinum Sponsors





Silver Sponsors





Supporters

GUNA HTA MEDICA REGENYAL T-LAB TOSHIBA
VSY BIOTECHNOLOGY
YURIA PHARM